TransMedics (TMDX) Current Deferred Revenue (2018 - 2026)

TransMedics has reported Current Deferred Revenue for 9 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 41.72% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (up 41.72% YoY), and the FY2025 full-year result was $2.9 million, up 66.76% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.9 million, up from $2.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $3.3 million in Q3 2025, with the low at $226000.0 in Q3 2022.
• Average Current Deferred Revenue over 5 years is $1.5 million, with a median of $1.7 million recorded in 2024.
• Year-over-year, Current Deferred Revenue slumped 42.82% in 2022 and surged 1063.27% in 2023.
• Tracing TMDX's Current Deferred Revenue over 5 years: stood at $241000.0 in 2022, then jumped by 713.69% to $2.0 million in 2023, then retreated by 11.17% to $1.7 million in 2024, then jumped by 66.76% to $2.9 million in 2025, then rose by 1.38% to $2.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.9 million (Q1 2026), $2.9 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.

Peer Comparison